Ebola infection is confirmed through laboratory testing, primarily RT PCR.

Testing is tightly controlled due to biosafety risks and is only performed for symptomatic individuals with epidemiologic risk factors.

The global Ebola diagnostics market is entering a new growth phase—reaching an estimated $1.18B in 2024 and projected to climb to $2.24B by 2033, driven by persistent outbreak risk and the need for rapid, scalable detection tools.

Today’s landscape spans molecular, immunoassay, and rapid diagnostic test manufacturers, including leaders developing PCR, antigen, and portable molecular platforms. As governments and global health organizations expand surveillance and outbreak response infrastructure, demand is rising for high-sensitivity PCR assays, deployable POC tools, and multiplex platforms capable of differentiating Ebola from other viral hemorrhagic fevers.

This creates a clear opportunity for diagnostics companies and investors: innovate toward faster, field-ready molecular testing while strengthening central lab PCR capacity in endemic regions. At GRN IVD Consulting, we help diagnostics manufacturers, investors, and global health partners navigate this evolving market with: • Competitive landscapes across PCR, antigen, and rapid test developers • Market sizing and forecasting for outbreak-driven and routine surveillance demand • Assay performance benchmarking and clinical algorithm mapping • Strategic insights to guide product positioning, partnerships, and global health engagement

If your team is evaluating opportunities in emerging infectious disease diagnostics, GRN IVD Consulting can help you see the market clearly—and act with precision. Let’s connect at grnivdconsulting@gmail.com